Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; hereinafter called “Sumitomo Dainippon Pharma”) announces that clinical data of napabucasin (BBI608) and amcasertib (BBI503) will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 3 to June 7, 2016.

Napabucasin: 6 presentations

1. ABSTRACT #3564, Poster #261: Saturday, June 4 from 8:00 a.m. – 11:30 a.m.:
   BBI608-246: NCT02024607: Phase Ib extension study of cancer stemness inhibitor BB608 (Napabucasin) administered in combination with FOLFIRI +/- Bevacizumab (Bev) in patients (pts) with advanced colorectal cancer (CRC).
   The abstract is now available on the official website of ASCO (http://abstracts.asco.org/176/AbstView_176_171370.html)

2. ABSTRACT #4128, Poster #120: Saturday, June 4 from 8:00 a.m. – 11:30 a.m.:
   BBI608-118: NCT02231723: A Phase Ib extension study of cancer stemness inhibitor BB608 (Napabucasin) in combination with Gemcitabine and nab-Paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.
   The abstract is now available on the official website of ASCO (http://abstracts.asco.org/176/AbstView_176_171329.html)

3. ABSTRACT #9093, Poster #416: Saturday, June 4 from 8:00 a.m. – 11:30 a.m.:
   The abstract is now available on the official website of ASCO (http://abstracts.asco.org/176/AbstView_176_171394.html)

4. ABSTRACT #1094, Poster #199: Sunday, June 5 from 8:00 a.m. – 11:30 a.m.:BBI608-201: NCT01325441: A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.
5. ABSTRACT #5578, Poster #401: Monday, June 6 from 1:00 p.m. – 4:30 p.m.: BBI608-118: NCT01325441: A Phase Ib/II Study of Cancer Stemness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Platinum Resistant Ovarian Cancer.

The abstract is now available on the official website of ASCO (http://abstracts.asco.org/176/AbstView_176_171455.html)

6. ABSTRACT #TPS4144, Poster #129b: Saturday, June 4 from 8:00 a.m. – 11:30 a.m.: BBI608-336: NCT02178956: The BRIGHTER trial: A phase III randomized double-blind study of BBI-608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.

The abstract is now available on the official website of ASCO (http://abstracts.asco.org/176/AbstView_176_171280.html)

Amcasertib: 1 presentation

1. ABSTRACT #6018, Poster #340: Saturday, June 4 from 1:00 p.m. – 4:30 p.m. (Poster Session) Saturday, June 4 from 4:45 p.m. – 6:00 p.m. (Poster Discussion Session): BBI503-101: NCT01781455: Phase I Extension Clinical Study of BB503, a First-in-Class Cancer Stemness Kinase Inhibitor, in Adult Patients with Advanced Head and Neck Cancer.

The abstract is now available on the official website of ASCO (http://abstracts.asco.org/176/AbstView_176_171512.html)

Reference information (napabucasin and amcasertib):

Napabucasin and amcasertib are investigational first-in-class anti-cancer drugs created and currently under development by Boston Biomedical, Inc. Napabucasin is an orally administered cancer stemness inhibitor designed to inhibit cancer stem cell pathways by targeting STAT3. Amcasertib is an orally administered agent designed to inhibit cancer stem cell pathways, including Nanog, by targeting stemness kinases.

Contact:
Public Relations/Investor Relations
Sumitomo Dainippon Pharma Co., Ltd.
TEL: +81-6-6203-1407 (Osaka)
+81-3-5159-3300 (Tokyo)